Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

N. C. Davidson, W. J. Coutie, D. J. Webb, A. D. Struthers

Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee.

OBJECTIVE: To assess the differential effects of low dose (5 mg) and high dose (20 mg) lisinopril treatment on cardiovascular hormones, renal function, and blood pressure over 24 hours in patients with heart failure. DESIGN: Double-blind crossover study. SETTING: Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee. PATIENTS: 19 patients with chronic heart failure and left ventricular ejection fraction < or = 45%. RESULTS: Plasma concentrations of aldosterone and endothelin were lower on the 20 mg dose (plasma aldosterone mean at peak drug effect: 90.7 v 152.0 pg/ml, P < 0.001; mean at trough effect: 124.7 v 174.4 pg/ml, P < 0.01; plasma endothelin at trough effect 4.70 v 6.04 pmol/l, P = 0.03). Creatinine clearance was lower on 20 mg lisinopril (68.7 v 82.1 ml/min, P < 0.05). The area under the curve for diastolic blood pressure over 24 hours was significantly lower on 20 mg (mean difference 3.0 mm Hg, P = 0.04); for systolic blood pressure there was a similar trend (mean difference 5.7 mmHg, P = 0.05). Plasma concentrations of atrial natriuretic peptide (ANP) and B-type natriuretic peptide were similar for both doses; urinary excretion of ANP was lower on 20 mg (12.2 v 13.6 pmol, P < 0.05). CONCLUSIONS: These results indicate that within the usual therapeutic range, high doses of lisinopril cause greater suppression of selected cardiovascular hormones than low doses in heart failure, but are associated with lower creatinine clearance in some patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Passino, C., Poletti, R., Bramanti, F., Prontera, C., Clerico, A., Emdin, M. (2006). Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. Eur J Heart Fail 8: 46-53 [Abstract] [Full Text]  
• Roffman, D. S (2004). High-Versus Low-Dose ACE Inhibitor Therapy in Chronic Heart Failure. The Annals of Pharmacotherapy 38: 831-838 [Abstract] [Full Text]  
• Clerico, A., Emdin, M. (2004). Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin. Chem. 50: 33-50 [Abstract] [Full Text]  
• Cooke, G.A., Williams, S.G., Marshall, P., Al-Timman, J.K., Shelbourne, J., Wright, D.J., Tan, L.-B. (2002). A mechanistic investigation of ACE inhibitor dose effects on aerobic exercise capacity in heart failure patients. Eur Heart J 23: 1360-1368 [Abstract] [Full Text]  
• Wilson Tang, W. H., Vagelos, R. H., Yee, Y.-G., Benedict, C. R., Willson, K., Liss, C. L., LaBelle, P., Fowler, M. B. (2002). Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 39: 70-78 [Abstract] [Full Text]  
• McMullan, R, Silke, B (2001). A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure. Postgrad. Med. J. 77: 765-768 [Abstract] [Full Text]  
• Schoolwerth, A. C., Sica, D. A., Ballermann, B. J., Wilcox, C. S. (2001). Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy: A Statement for Healthcare Professionals From the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104: 1985-1991 [Full Text]  
• Yee, K.-M., Pringle, S. D., Struthers, A. D. (2001). Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37: 1800-1807 [Abstract] [Full Text]  
• Gomberg-Maitland, M., Baran, D. A., Fuster, V. (2001). Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist. Arch Intern Med 161: 342-352 [Abstract] [Full Text]  
• Nanas, J. N., Alexopoulos, G., Anastasiou-Nana, M. I., Karidis, K., Tirologos, A., Zobolos, S., Pirgakis, V., Anthopoulos, L., Sideris, D., Stamatelopoulos, S. F., Moulopoulos, S. D., for the High Enalapril Dose Study Group, (2000). Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 36: 2090-2095 [Abstract] [Full Text]  
• Struthers, A. D., MacFadyen, R., Fraser, C., Robson, J., Morton, J. J., Junot, C., Ezan, E. (1999). Nonadherence with angiotensin-converting enzyme inhibitor therapy: A comparison of different ways of measuring it in patients with chronic heart failure. J Am Coll Cardiol 34: 2072-2077 [Abstract] [Full Text]  
• Struthers, A D, Anderson, G, MacFadyen, R J, Fraser, C, MacDonald, T M (1999). Non-adherence with ACE inhibitor treatment is common in heart failure and can be detected by routine serum ACE activity assays. Heart 82: 584-588 [Abstract] [Full Text]  
• MacFadyen, R J, Lee, A F C, Morton, J J, Pringle, S D, Struthers, A D (1999). How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart 82: 57-61 [Abstract] [Full Text]  
• Brunner-La Rocca, H. P., Vaddadi, G., Esler, M. D. (1999). Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol 33: 1163-1173 [Abstract] [Full Text]  
• Rocca, H. P. B.-L., Weilenmann, D., Kiowski, W., Maly, F. E., Follath, F. (1999). Plasma Levels of Enalaprilat in Chronic Therapy of Heart Failure: Relationship to Adverse Events. J. Pharmacol. Exp. Ther. 289: 565-571 [Abstract] [Full Text]  
• van Veldhuisen, D. J., Genth-Zotz, S., Brouwer, J., Boomsma, F., Netzer, T., Man in 't Veld, A. J., Pinto, Y. M., Lie, K. I., Crijns, H. J. G. M. (1998). High- versus low-dose ACE inhibition in chronic heart failure: A double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 32: 1811-1818 [Abstract] [Full Text]  
• Hulsmann, M., Stanek, B., Frey, B., Sturm, B., Putz, D., Kos, T., Berger, R., Woloszczuk, W., Maurer, G., Pacher, R. (1998). Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32: 1695-1700 [Abstract] [Full Text]